Vaccines are needed to protect from SARS-CoV-2, the virus causing COVID-19. Vaccines that induce large quantities of high affinity virus-neutralizing antibodies may optimally prevent infection and avoid unfavorable effects. Vaccination trials require precise clinical management, complemented with detailed evaluation of safety and immune responses. Here, we review the pros and cons of available vaccine platforms and options to accelerate vaccine development towards the safe immunization of the world’s population against SARS-CoV-2. Favorable vaccines, used in well-designed vaccination strategies, may be critical for limiting harm and promoting trust and a long-term return to normal public life and economy.
All Keywords
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, Immunity, serology, nucleic acid tests, 【초록키워드】 Vaccine development, Trial, Vaccines, Infection, virus, immunization, immune responses, Vaccination strategies, Clinical management, vaccine platform, Critical, Safe, high affinity, Effects, Prevent, virus-neutralizing antibody, PROTECT, induce, accelerate,
【저자키워드】 COVID-19, SARS-CoV-2, vaccination, Immunity, serology, nucleic acid tests, 【초록키워드】 Vaccine development, Trial, Vaccines, Infection, virus, immunization, immune responses, Vaccination strategies, Clinical management, vaccine platform, Critical, Safe, high affinity, Effects, Prevent, virus-neutralizing antibody, PROTECT, induce, accelerate,